EXEL Valuation

Exelixis Inc

Add to Watchlist

Advanced Chart

37.760

-0.55(-1.436%)1D

Overview
Forecast
Valuation
Earnings

EXEL Relative Valuation

EXEL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EXEL is overvalued; if below, it's undervalued.

Historical Valuation

Exelixis Inc (EXEL) is now in the Undervalued zone, suggesting that its current forward PE ratio of 14.47 is considered Undervalued compared with the five-year average of 31.34. The fair price of Exelixis Inc (EXEL) is between 70.87 to 141.58 according to relative valuation methord. Compared to the current price of 37.76 USD , Exelixis Inc is Undervalued By 46.72%.

Relative Value

Fair Zone

70.87-141.58

Current Price：37.76

46.72%

Undervalued

14.47

Trailing

Forward

9.44

EV/EBITDA

Exelixis Inc. (EXEL) has a current EV/EBITDA of 9.44. The 5-year average EV/EBITDA is 18.78. The thresholds are as follows: Strongly Undervalued below -3.35, Undervalued between -3.35 and 7.72, Fairly Valued between 29.84 and 7.72, Overvalued between 29.84 and 40.91, and Strongly Overvalued above 40.91. The current Forward EV/EBITDA of 9.44 falls within the Historic Trend Line -Fairly Valued range.

11.20

EV/EBIT

Exelixis Inc. (EXEL) has a current EV/EBIT of 11.20. The 5-year average EV/EBIT is 22.66. The thresholds are as follows: Strongly Undervalued below -2.38, Undervalued between -2.38 and 10.14, Fairly Valued between 35.18 and 10.14, Overvalued between 35.18 and 47.70, and Strongly Overvalued above 47.70. The current Forward EV/EBIT of 11.20 falls within the Historic Trend Line -Fairly Valued range.

4.14

Exelixis Inc. (EXEL) has a current PS of 4.14. The 5-year average PS is 4.08. The thresholds are as follows: Strongly Undervalued below 2.16, Undervalued between 2.16 and 3.12, Fairly Valued between 5.04 and 3.12, Overvalued between 5.04 and 6.00, and Strongly Overvalued above 6.00. The current Forward PS of 4.14 falls within the Historic Trend Line -Fairly Valued range.

11.47

P/OCF

Exelixis Inc. (EXEL) has a current P/OCF of 11.47. The 5-year average P/OCF is 17.75. The thresholds are as follows: Strongly Undervalued below 7.43, Undervalued between 7.43 and 12.59, Fairly Valued between 22.91 and 12.59, Overvalued between 22.91 and 28.07, and Strongly Overvalued above 28.07. The current Forward P/OCF of 11.47 falls within the Undervalued range.

15.12

P/FCF

Exelixis Inc. (EXEL) has a current P/FCF of 15.12. The 5-year average P/FCF is 22.43. The thresholds are as follows: Strongly Undervalued below 9.50, Undervalued between 9.50 and 15.96, Fairly Valued between 28.90 and 15.96, Overvalued between 28.90 and 35.37, and Strongly Overvalued above 35.37. The current Forward P/FCF of 15.12 falls within the Undervalued range.

Exelixis Inc (EXEL) has a current Price-to-Book (P/B) ratio of 5.02. Compared to its 3-year average P/B ratio of 3.26 , the current P/B ratio is approximately 53.94% higher. Relative to its 5-year average P/B ratio of 3.24, the current P/B ratio is about 54.64% higher. Exelixis Inc (EXEL) has a Forward Free Cash Flow (FCF) yield of approximately 7.31%. Compared to its 3-year average FCF yield of 5.28%, the current FCF yield is approximately 38.43% lower. Relative to its 5-year average FCF yield of 4.94% , the current FCF yield is about 47.94% lower.

5.02

P/B

Median3y

3.26

Median5y

3.24

7.31

FCF Yield

Median3y

5.28

Median5y

4.94

Competitors Valuation Multiple

The average P/S ratio for EXEL's competitors is 60.97, providing a benchmark for relative valuation. Exelixis Inc Corp (EXEL) exhibits a P/S ratio of 4.14, which is -93.21% above the industry average. Given its robust revenue growth of -10.82%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Madrigal Pharmaceuticals Inc

Performance Decomposition

Market capitalization of EXEL increased by 45.06% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 11.07 to 18.18.

The secondary factor is the Margin Expansion, contributed -8.34%to the performance.

Overall, the performance of EXEL in the past 1 year is driven by P/E Change. Which is more unsustainable.

-10.82%

637.18M → 568.26M

Revenue Growth

-8.34%

35.49 → 32.53

Margin Expansion

64.22%

11.07 → 18.18

P/E Change

45.06%